Intelligent Bio Solutions Inc. (NASDAQ: INBS) has marked a significant expansion in the U.S. forensic use-only market, thanks to its strategic partnership with SMARTOX, a Texas-based leader in drug and alcohol screening services. This collaboration has led to the deployment of over 50 INBS Intelligent Fingerprinting Drug Screening Readers and the conduction of more than 7,000 tests, including over 1,500 in 2024 alone. The technology, which uses fingerprint sweat for drug detection, presents a non-invasive alternative to traditional urine and saliva tests, enhancing efficiency and user dignity in corrections, rehabilitation, and drug court settings.
The importance of this development lies in the growing demand for rapid, non-invasive drug testing solutions that can provide quick and accurate results. INBS's technology, capable of delivering results in under ten minutes, is poised to revolutionize drug screening processes across various sectors. Furthermore, the company is seeking FDA clearance for its codeine opiate test, with ambitions to enter the workplace drug testing market later this year. This move could significantly impact safety-critical industries by offering a hygienic, cost-effective, and efficient testing solution.
The partnership between INBS and SMARTOX underscores the potential for innovative technologies to transform traditional drug screening methods. By addressing the limitations of current testing procedures, INBS's fingerprint sweat-based system could set a new standard for drug detection, offering implications not just for the forensic and workplace testing markets, but also for broader applications in public health and safety.
